altimmune
uab
announce
publication
compelling
data
intranasal
vaccine
candidate
comprehensive
analysis
shows
adcovid
uniquely
stimulates
three
key
immune
components
serum
neutralizing
antibody
cell
responses
mucosal
immunity
respiratory
tract
nasal
mucosal
immunity
may
critical
factor
driving
sterilizing
immunity
preventing
spread
virus
vaccinated
individuals
gaithersburg
globe
newswire
altimmune
nasdaq
alt
biopharmaceutical
company
today
comprehensive
preclinical
evaluation
intranasal
vaccine
candidate
adcovid
manuscript
entitled
intranasal
administration
adcovid
elicits
systemic
mucosal
immunity
studies
conducted
part
altimmune
ongoing
collaboration
university
alabama
birmingham
uab
expand
upon
earlier
preclinical
data
presented
adcovid
program
manuscript
available
online
preprint
server
content
adcovid
based
company
intranasal
vaccine
platform
expresses
receptor
binding
domain
rbd
spike
protein
rbd
essential
viral
infection
majority
neutralizing
antibodies
people
recovered
bind
rbd
highlighting
importance
rbd
controlling
infection
adcovid
designed
offer
significant
advantages
vaccine
approaches
including
intranasal
administration
effectiveness
broad
activation
immune
response
ability
ship
store
vaccine
conveniently
inexpensively
altimmune
anticipates
filing
ind
food
drug
administration
commencing
phase
safety
immunogenicity
trial
adcovid
fourth
quarter
key
findings
study
publication
authors
present
data
demonstrating
strong
activation
three
arms
adaptive
immune
system
following
single
intranasal
dose
adcovid
data
conducted
two
strains
mice
show
adcovid
stimulated
strong
immune
responses
including
serum
neutralizing
immunity
adcovid
elicited
median
serum
neutralization
titer
virus
focus
reduction
neutralization
test
frnt
context
level
neutralizing
activity
least
higher
minimum
titer
recommended
fda
convalescent
plasma
used
treatment
adcovid
elicited
median
serum
neutralization
titer
virus
focus
reduction
neutralization
test
frnt
context
level
neutralizing
activity
least
higher
minimum
titer
recommended
fda
convalescent
plasma
used
treatment
cell
immunity
adcovid
stimulated
cell
responses
following
single
intranasal
vaccination
response
focused
lungs
vaccinated
mice
biased
toward
cells
significant
fraction
cells
lung
found
memory
trm
cells
shown
play
role
fighting
respiratory
viral
infections
adcovid
stimulated
cell
responses
following
single
intranasal
vaccination
response
focused
lungs
vaccinated
mice
biased
toward
cells
significant
fraction
cells
lung
found
memory
trm
cells
shown
play
role
fighting
respiratory
viral
infections
mucosal
immunity
nasal
mucosal
immunity
local
type
immunity
potential
stop
infection
transmission
virus
significantly
intranasal
vaccine
activate
important
type
immunity
adcovid
induced
increase
mucosal
iga
specific
rbd
well
level
associated
protection
clinical
studies
mucosal
influenza
vaccines
increase
iga
found
correlated
protection
observed
iga
response
together
trm
cell
response
noted
provided
additional
level
immune
response
may
provide
enhanced
protection
disease
transmission
collaboration
uab
extremely
productive
preclinical
data
adcovid
continue
show
promising
differentiation
vaccine
candidates
said
scot
roberts
chief
scientific
officer
altimmune
intranasal
vaccination
represents
attractive
strategy
prevent
infection
nasal
cavity
comprises
first
line
defense
virus
prior
entry
lungs
stimulating
mucosal
antibody
cell
immunity
along
potent
systemic
neutralizing
antibody
titers
three
arms
immune
system
work
concert
prevent
control
roberts
continued
current
vaccines
given
intramuscular
injection
unable
activate
nasal
mucosal
immunity
may
critical
mounting
comprehensive
immune
response
may
also
prevent
spread
virus
blocking
transmission
delighted
work
provided
convincing
data
potential
adcovid
provide
broad
effective
immune
response
look
forward
continued
collaboration
altimmune
important
program
said
frances
lund
charles
mccauley
professor
chair
uab
department
microbiology
principal
investigator
manuscript
adcovid
adcovid
designed
offer
several
important
advantages
vaccine
approaches
including
intranasal
administration
broad
immune
response
includes
mucosal
immunity
ability
ship
store
vaccine
conveniently
inexpensively
expected
attributes
adcovid
single
dose
protection
mucosal
systemic
immunity
block
infection
transmission
nasal
spray
potential
excellent
tolerability
profile
attractive
stability
profile
cold
distribution
intranasal
dosing
stimulate
local
mucosal
immunity
adcovid
expected
guard
respiratory
tract
viral
invasion
provide
downstream
protection
viral
spread
local
mucosal
immunity
may
essential
creating
sterilizing
immunity
eliminates
last
traces
viral
infection
nasal
cavity
recent
studies
shown
absence
mucosal
immunity
nasal
cavity
may
become
reservoir
coronavirus
potentially
prolonging
infection
allowing
disease
transmission
importantly
nasal
mucosal
immunity
achieved
administering
vaccine
intranasally
adcovid
also
provides
easier
route
administration
injection
may
eliminate
need
administration
trained
medical
personnel
may
even
allow
finally
based
data
altimmune
platform
vaccines
adcovid
expected
extended
stability
room
temperature
allowing
cold
distribution
vaccine
stored
common
refrigerators
found
doctor
offices
pharmacies
two
years
simple
convenient
handling
requirements
may
greatly
increase
number
people
willing
take
vaccine
altimmune
altimmune
clinical
stage
biopharmaceutical
company
focused
developing
intranasal
vaccines
immune
modulating
therapies
treatments
liver
disease
diverse
pipeline
includes
proprietary
intranasal
vaccines
anthrax
influenza
intranasal
immune
modulating
therapeutic
next
generation
peptide
therapeutics
nash
chronic
hepatitis
b
information
altimmune
please
visit
statement
statements
made
press
release
relating
future
financial
business
performance
conditions
plans
prospects
trends
strategies
financial
business
matters
including
without
limitation
submitting
ind
food
drug
administration
commencing
phase
safety
immunogenicity
trial
adcovid
fourth
quarter
potential
immunization
effects
adcovid
ability
manufacture
adcovid
beginning
year
prospects
regulatory
approval
commercializing
selling
product
drug
candidates
statements
within
meaning
private
securities
litigation
reform
act
addition
used
press
release
words
may
could
anticipate
believe
estimate
expect
intend
plan
predict
similar
expressions
variants
relate
altimmune
company
may
identify
statements
company
cautions
statements
subject
numerous
assumptions
risks
uncertainties
change
time
important
factors
may
cause
actual
results
differ
materially
results
discussed
forward
looking
statements
historical
experience
include
risks
uncertainties
including
risks
relating
potential
impacts
due
pandemic
delays
regulatory
review
manufacturing
supply
chain
interruptions
access
clinical
sites
enrollment
adverse
effects
healthcare
systems
disruption
global
economy
reliability
results
studies
relating
human
safety
possible
adverse
effects
resulting
administration
company
product
candidates
company
ability
secure
regulatory
approval
adcovid
investigational
new
drug
application
submission
food
drug
administration
company
ability
manufacture
clinical
trial
materials
timelines
anticipated
success
future
product
advancements
including
success
future
clinical
trials
information
factors
risks
could
affect
company
business
financial
conditions
results
operations
contained
company
filings
securities
exchange
commission
including
heading
risk
factors
company
annual
report
form
fiscal
year
ended
december
quarterly
report
form
quarter
ended
march
filed
sec
available
